Bruker Corporation Investor Day 2023
■
■
INVESTOR DAY 2023
Dual strategy of Project Accelerate 2.0 and Operational Excellence works
Project Accelerate 2.0 Initiatives
Pull up growth and margins
Re-positioning Bruker for high-growth, high-
margin opportunities
Innovating to push envelope in sensitivity,
resolution, quantification, throughput.
Building unique, leading platforms for
novel applications, life-science solutions
Solving complex biology in large TAMs with
strong secular growth
▪ Project Accelerate 2.0 at ~56% of revenue,
with DD revenue CAGR
2023 Bruker
Assays, Software
& Aftermarket
Next-gen Nano
& Semi Tools
Unbiased
Proteomics &
Multiomics
BRUKER
Biopharma &
Applied
Microbiology &
Molecular Dx
Spatial Biology,
Single-Cell Omics,
Cellular Analysis
BRUKER
Operational Excellence
▪ Pushes up market share, margins
▪ Cadence and control of Bruker
Management Process drives
execution and predictability
▪ Includes commercial and product
R&D excellence
▪ Disciplined financial execution:
significant investments and
margin expansion, high ROIC
▪ Prudent capital allocation with
conservative margin of safety
Innovation with Integrity |
June 15, 2023
I
8View entire presentation